It’s been an excellent year for stocks amid a resilient macroeconomic backdrop. The S&P 500 index is up 20% year to date with several high-profile companies delivering spectacular returns heading into 2025. At the same time, not all stocks have rallied alongside the market. Looking at some of the laggards can sometimes uncover a high-quality gem that has been beaten down but with the potential to stage a big turnaround.
Let’s explore two magnificent stocks near a 52-week low to buy now.
Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
Pharmaceutical giant Merck (NYSE: MRK) is recognized for its extensive product portfolio of more than 52 drugs covering categories like vaccines, hospital acute care, cardiology, virology, and diabetes medications. While a long history of innovation has rewarded shareholders historically, the stock has been under pressure, down 6% this year.
The weakness continued following a mixed third-quarter earnings report (for the period ended Sept. 30) where solid financial results were overshadowed by muted management guidance. In this case, Merck narrowed its forecast for annual revenue growth to a range of 6% to 7% while modestly revising the 2024 adjusted earnings per share (EPS) target lower to between $7.72 and $7.77, representing a 4% increase from the prior annual record in 2022.
The main headwind preventing even stronger growth is weak sales of the company’s Gardasil vaccine against human papillomavirus (HPV) in China that management sees extending into 2025 as distributors rebalance inventories. The market is also wondering how Merck may eventually need to find a replacement for its top-selling Keytruda immunotherapy drug set to lose patent exclusivity by 2028.
Ultimately, these concerns could be overdone as Merck remains well-positioned to deliver more profitable growth through a wide drug development pipeline, including new indications for Keytruda. Even the group’s smaller animal health segment is also contributing positively.
A pickup in sales from different parts of its portfolio can be a catalyst for the stock to rebound higher in 2025. Shares trading at 13 times its 2024 EPS estimate as a forward price-to-earnings (P/E) ratio may be a bargain if Merck begins to outperform its low bar of expectations to leverage earnings higher.
Shares of Pfizer (NYSE: PFE) are currently trading 12% above their 52-week low, but still disappointing shareholders, trailing the broader market in recent years. The global blue chip biopharma company is attempting to move past the overhang of the record pandemic COVID-19 vaccine sales and earnings by convincing the market it has other growth drivers.
